Get started
JOHNSON & JOHNSON COM USD1JOHNSON & JOHNSON COM USD1JOHNSON & JOHNSON COM USD1

JOHNSON & JOHNSON COM USD1

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

0R34 trade ideas

Do These 4 Steps To Understand A Short Squeeze MindsetYou believe trading the new high is very hard.You have have heard of pump and dump.This is when someone promotes A stock price and "wham!" The stock crashes on you. Maybe you tried using the ADX or DMI indicator and you lost your marbles or mind trying to catch the trend. Yesterday I felt like a total loser because my trading strategy was not working "I understand the Rocket Booster strategy but why is the volatility kicking my butt?" Just like you my indicators stopped working. But there is a solution it's called the short squeeze mindset. Let me tell you how I discovered it. 👉I started thinking using a research tool on trading. 👉I remembered that the best way to measure ranges of price action is using candlesticks patterns So how do you master candlestick patterns? You need to change time-frames In this case I am using the daily time frame. On this timeframe I found a Green bar 🟩 Then I switched to the 4hour time frame and found a red bar 🟥 Thats the short squeeze mindset. So let's list the steps I used so that you can learn to use them as well. 1️⃣The Rocket Booster Strategy 2️⃣The Momentum Trading Style 3️⃣The Short Squeeze Mindset 4️⃣The Stochastic Overbought Zone Combining these 4 steps helped me find the breakout pattern in this stock. Right now do the following: 1️⃣Check the daily chart 2️⃣Do you see the green bar 🟩? 3️⃣Check the 4 hour chart 4️⃣Do you see the red bar 🟥? That's the short squeeze mindset.Its the key to price action entry. You have no excuse if you did the steps above you now see that it is possible to understand the short squeeze mindset. But you need to do this exercise on top before the market opens today.. because this pattern will disappear after the market opens today. So this is your chance to see it. If you are reading this days in the future dont worry. At least you have an idea of what it is.So stayed tuned to these articles for more practical examples. Remember to 🚀 Rocket Boost This Content To Learn More. Disclaimer ⚠️ Trading is risky please learn about risk management and profit taking strategies.Also use a simulation trading account before you use real money.
NYSE:JNJLong
by lubosi
JNJ AUG - 2025Johnson & Johnson ( NYSE:JNJ ) continues its bullish structure, holding above the 170 support zone with institutional absorption visible in recent candles. Price is approaching upper channel resistance, with momentum pointing toward 185 as the next target if trend strength holds. Key supports remain at 170 and 160, with an open gap toward 155 that may act as a magnet if momentum fades. Upside target: 185 Downside target: 160–155 gap #JNJ #globaltrade #investment #investing #stockmarket #wealth #realestate #markets #economy #finance #money #forex #trading #price #business #currency #blockchain #crypto #cryptocurrency #airdrop #btc #ethereum #ico #altcoin #cryptonews #Bitcoin #ipo
NYSE:JNJLong
by alexpv73
Johnson & Johnson Wave Analysis – 11 August 2025- Johnson & Johnson broke the resistance level 168.15 - Likely to rise to level 175.95 Johnson & Johnson previously broke the resistance level 168.15 (upper border of the weekly sideways price range inside which the price has been trading from 2023). The breakout of the resistance level 168.15 accelerated the active medium-term impulse wave (3) from July. Johnson & Johnson can be expected to rise further to the next resistance level 175.95, a former multi-month high from 2023 and the target price for the completion of the active impulse wave (3).
NYSE:JNJLong
by FxProGlobal
Johnson & Johnson. Clean. Soft. Gentle. Growth.Johnson & Johnson (JNJ) stands out as a bellwether in the global healthcare sector, and its nearly 18% stock performance in 2025 reflects both robust fundamentals and compelling technical trends. Fundamental Perspective JNJ maintains a solid financial foundation, underpinned by consistently strong profitability, a diversified business model, and effective capital allocation. As of August 2025, JNJ reported trailing twelve-month (TTM) revenue of $90.6 billion and earnings of $22.7 billion, resulting in a net profit margin of 25% and a gross margin close to 68%. Key profitability metrics such as a Return on Assets (ROA) of 11.7%, Return on Equity (ROE) of 28.9%, and Return on Invested Capital (ROIC) of 13.6% underscore the company's operational efficiency relative to peers in the pharmaceutical industry. From a financial health perspective, JNJ maintains moderate leverage, with a debt/equity ratio of 0.61 and an Altman-Z score of 4.17, signifying financial stability and a low risk of distress. The forward price/earnings (P/E) ratio is 14.9, suggesting that the stock is not particularly expensive for its sector, while the dividend yield remains attractive at 3.16%, appealing to income-oriented investors. The company’s free cash flow yield and high profit quality further enhance its fundamental appeal. JNJ's growth narrative is fueled primarily by its Innovative Medicine and MedTech segments. Drugs like Darzalex and Tremfya continue to deliver high single- to double-digit year-over-year growth, and the MedTech segment is experiencing margin expansion due to scale and product mix improvements. Strategic acquisitions (notably Intra-Cellular Therapies), new regulatory approvals, and a deep late-stage pipeline (over 40 programs) provide resilience and new growth avenues, offsetting pressures from biosimilar competition, patent expirations, and legal settlements. Technical Perspective On the technical side, JNJ’s stock has demonstrated significant momentum. The price reached an all-time 52-week high above $170 per share in early August 2025, following Q2 earnings that exceeded expectations and prompted a nearly 6% surge in share price. Technical indicators are largely positive, with the stock trading above its 50-day and 200-day simple moving averages ($157.43 and $155.56, respectively), reflecting a prevailing bullish trend. The 14-day Relative Strength Index (RSI) stands at 55.85—neither overbought nor oversold—implying stable investor sentiment. Analyst price targets average $173, reflecting modest but continued upside. A key technical resistance zone had developed around $167, which NYSE:JNJ has recently breached. The consensus among technical analysts is the potential for a substantial upward move towards $194 if the breakout holds, while support remains strong at around $140—historically a level where dip buyers emerge. Market sentiment remains bullish, with the Fear & Greed Index indicating broader market caution, while JNJ’s own technical indicators show "Strong Buy". In long-term, JNJ has been supported earlier in 2025 by 10-year SMA, above which stocks are moving since 1980s, i.e. for the past 45 years (on end of year basis). In mid-term, the main technical graph indicates on major 5-year old bearish trend reversal. Reasons for Recent Growth JNJ’s recent growth is attributed to several convergent factors: Strong Q2 2025 earnings performance, leading management to raise full-year revenue and EPS guidance above analysts’ expectations. Continued strength in key growth drivers: new drug launches in oncology and immunology, robust MedTech expansion, and improved operating margins. Favorable foreign exchange and a reduction in tariff costs, redirecting capital to R&D. Positive pipeline developments and strategic acquisitions. Successful navigation of legal risks and clarity regarding settlements (including talc litigation), which have reduced major uncertainties. Broad overall market resilience and a rotation toward defensive healthcare shares. In summary, Johnson & Johnson’s combination of strong and diversified fundamentals, attractive income profile, and bullish technical signals—amplified by improved guidance and innovation momentum—help explain the stock’s recent appreciation and continued investor confidence. -- Best wishes, @PandorraResearch Team
NYSE:JNJ
by PandorraResearch
Johnson & Johnson | JNJ | Long at $146.00Johnson & Johnson NYSE:JNJ is strong (but highly controversial) company with anticipated earnings growth on the horizon. With a P/E of 23x, steady dividend growth record, low debt, and expected increased cashflow, the future is optimistic for NYSE:JNJ if they can stay out of the shady spotlight... While the historical simple moving average I've selected suggests the stock is entering a downtrend on the daily chart, I'm going to go against this given the current price/position it is in. If the price can hold in $140's and then move up, there could be an early cup formation here. However, if the price drops below $140, that idea is out, and the near-term downtrend may be on. But the company, overall, is a personal buy-and-hold for the long-term ups and downs (unless new news points the company in a different direction). Thus, at $146.00, NYSE:JNJ is in a personal buy-zone. Target #1 = $157.00 Target #2 = $165.00 Target #3 = $170.00+
NYSE:JNJLong
by WorthlessViews
Johnson & Johnson Wave Analysis – 31 July 2025 Johnson & Johnson reversed from the resistance zone - Likely to fall to support level 160.00 Johnson & Johnson recently reversed down from the strong resistance zone located between the long-term resistance level 168.15 (upper border of the weekly sideways price range from 2023) and the upper weekly Bollinger Band. The downward reversal from this resistance zone stopped the earlier intermediate impulse wave (3). Given the strength of the resistance level 168.15 and the overbought weekly Stochastic, Johnson & Johnson can be expected to fall to the next support level 160.00.
NYSE:JNJShort
by FxProGlobal
JOHNSON & JOHNSON Sell opportunity on a Double Resistance.It's been 9 months (October 11 2024, see chart below) since our last Johnson & Johnson (JNJ) analysis, where we gave a very timely sell signal that surgically hit our $141.00 Target: The Channel Down has since broke to the upside and a new Higher Lows structure has emerged but with a clear Resistance Zone for the time being. At the same time, the price is also just below the Higher Highs trend-line that started on the September 04 2024 High. With the 1D RSI overbought (same as on February 25 2025), we don't give the upside much room to go, so we turn bearish here, targeting the 0.382 Fibonacci extension and Higher Lows trend-line at $160.00. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJShort
by TradingShot
JNJ - Macro View 🌐Hello TradingView Family / Fellow Traders. This is Richard, also known as theSignalyst. 📈 JNJ has exhibited an overall bullish trend, trading within the ascending wedge pattern outlined in blue. It is presently nearing the lower boundary/blue trendline. At present, JNJ is undergoing a correction phase and is trading within the descending red channel. It is currently approaching the lower limit and a highlighted demand zone in green. 🏹 Thus, the highlighted purple circle is a strong area to look for buy setups as it is the intersection of the green demand and lower blue and red trendlines acting as a non-horizontal support. 📚 As per my trading style: As JNJ approaches the lower purple circle zone, I will be looking for bullish reversal setups (like a double bottom pattern, trendline break , and so on...) 📚 Always follow your trading plan regarding entry, risk management, and trade management. Good luck! All Strategies Are Good; If Managed Properly! ~Rich
NYSE:JNJ
by TheSignalyst
3
JOHNSON AND JOHNSON: Re-accumulation is targeting $175.JNJ is neutral on its 1D technical outlook (RSI = 49.991, MACD = -1.040, ADX = 18.184) as it's only trading around its 1W MA50 but having made an impressive rebound 4 weeks ago inside the Demand Zone. This is the 4th time this Demand Zone provided a rally and the last one even crossed over the 3 year LH trendline that kept the stock on a downtrend since 2022. The breakout confirmed the emergence of a HH trendline which is taking the stock on a new multiyear bullish path. We expect at least one more high on the HH before the end of the year (TP = 175.00). ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:JNJLong
by InvestingScope
Buy JNJ for Stable Gains Amid Earnings Optimism Next Week - Key Insights: Johnson & Johnson demonstrated robust earnings performance with an EPS of $2.77, surpassing consensus estimates and reinforcing its defensive stock status. Its diverse portfolio and consistent ability to execute in volatile markets make it a strong candidate for growth-oriented and stability-focused investors. With a positive sentiment surrounding large-cap equities, JNJ is likely to continue attracting capital. - Price Targets: Next week targets for LONG positions: T1=$166, T2=$170. Stop levels: S1=$157, S2=$155. - Recent Performance: JNJ outperformed expectations in its latest earnings report, showcasing profitability and resilience in the face of broader economic headwinds. The company delivered solid results while navigating inflationary pressures, confirming its strength as a defensive player in the healthcare marketplace. - Expert Analysis: Analysts remain optimistic about JNJ’s execution capabilities, citing its strategic investments in R&D and global footprint. The earnings beat is seen as a validation of management’s effectiveness in maximizing profitability through cost controls, alongside maintaining strong demand across pharmaceuticals, medical devices, and consumer health segments. - News Impact: Broader market optimism surrounding strong earnings across top- tier corporations (e.g., Abbott, Goldman Sachs) enhances JNJ’s prospects for an earnings-season rally. Sector-wide attention on healthcare innovation further bolsters JNJ’s defensive appeal amid global health concerns, while its pricing power shields it from inflationary impacts.
NYSE:JNJLong
by CrowdWisdomTrading
Johnson & Johnson Wave Analysis – 18 April 2025 - Johnson & Johnson rising inside weekly price range - Likely to test resistance level 165.60 Johnson & Johnson continues to rise in the primary upward impulse wave 3, which started earlier from the major support level 145.00 (lower border of the weekly sideways price range from 2023). The upward reversal from the support level 145.00 previously formed the weekly Japanese candlesticks reversal pattern Hammer Doaji – which reflected the strength of this price level. Johnson & Johnson can be expected to rise to the next resistance level 165.60, the upper border of the active sideways price range.
NYSE:JNJLong
by FxProGlobal
Johnson & Johnson Beats Q1 Estimates, Premarket Not Doing WellJohnson & Johnson (NYSE: NYSE:JNJ ) on Tuesday reported better-than-expected Q1 results and lifted its sales forecast for the full year. Johnson & Johnson (NYSE: NYSE:JNJ ), together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide, operating in two segments, Innovative Medicine and MedTech. Posted adjusted earnings per share (EPS) of $2.77 on revenue of $21.89 billion. However, analysts had expected $2.56 and $21.56 billion, respectively, according to estimates compiled by Visible Alpha. Price Action Shares of Johnson & Johnson (NYSE: NYSE:JNJ ) were up about 1% immediately following the report, but the uptick was shortlived as the stock is down -0.54% in premarket trading. They entered the day up about 7% since the start of the year. The company lifted its projected sales range to $91.0 billion to $91.8 billion, up from $89.2 billion to $90.0 billion previously. It also held its adjusted EPS forecast steady at $10.50 to $10.70, "including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange." Since reporting a disappointing 2025 sales outlook in January, the company closed its nearly $15 billion acquisition of Intra-Cellular Therapies and announced plans to lift its U.S. investment to more than $55 billion over the next four years.23 Technical Outlook Shares of NYSE:JNJ closed Monday's session up 1.73% and despite the Q1 Earnings beat, the premarket session tells a different story as the asset is down 0.54% in Tuesday's session. The asset is trading within an enclosed rectangular formation with a perfectly formed support and resistant zones as indicated in the chart. A break above the the key moving averages could cement a bullish breakout that may resort to a break above the $169 resistant point. With the RSI at 45.35, NYSE:JNJ is well positioned for a bullish campaign once traders digest the earnings news.
NYSE:JNJLong
by DEXWireNews
Johnson & Johnson (JNJ) Shares Drop Over 7%Johnson & Johnson (JNJ) Shares Drop Over 7% As the chart shows, Johnson & Johnson (JNJ) shares declined by approximately 7.6%, reaching their lowest level since late February. This marked one of the worst performances in the stock market yesterday. Why Did JNJ Shares Fall? Two major bearish factors contributed to the decline: A Texas judge rejected Johnson & Johnson's third attempt to settle lawsuits related to allegations that its baby powder and other talc-based products harmed consumers. On Tuesday, Johnson & Johnson announced that its upcoming acquisition of Intra-Cellular Therapies is expected to dilute adjusted earnings per share by approximately $0.25 for the full year 2025. Investors appear to have reacted negatively to this outlook, despite the company’s expectation that the deal will generate around $700 million in additional sales. Technical Analysis of JNJ Stock Chart Price movements in 2025 have formed an ascending channel (marked in blue), with indicators highlighting how: → The channel’s boundaries have acted as support and resistance levels. → The channel’s median line has served as a “magnet” for price action, reflecting the balance between supply and demand. As JNJ's share price approaches the lower boundary (circled), just above the psychological support level at $150—previously a key level in February—traders have reasons to anticipate that the decline may slow down or even lead to a significant rebound from this support area. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:JNJ
by FXOpen